IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC).

TitleIGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC).
Publication TypeJournal Article
Year of Publication2006
AuthorsRinaldi, S, Peeters, PHM, Berrino, F, Dossus, L, Biessy, C, Olsen, A, Tjonneland, A, Overvad, K, Clavel-Chapelon, F, Boutron-Ruault, MC, Téhard, B, Nagel, G, Linseisen, J, Boeing, H, Lahmann, PH, Trichopoulou, A, Trichopoulos, D, Koliva, M, Palli, D, Panico, S, Tumino, R, Sacerdote, C, van Gils, CH, van Noord, P, Grobbee, DE, Bueno-de-Mesquita, HB, González, CA, Agudo, A, Chirlaque, MD, Barricarte, A, Larrañaga, N, Quiros, JR, Bingham, S, Khaw, KT, Key, T, Allen, NE, Lukanova, A, Slimani, N, Saracci, R, Riboli, E, Kaaks, R
JournalEndocr Relat Cancer
Volume13
Issue2
Pagination593-605
Date Published2006 Jun
ISSN1351-0088
KeywordsAdult, Breast Neoplasms, Case-Control Studies, Europe, Female, Humans, Incidence, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I, Middle Aged, Nutritional Physiological Phenomena, Risk Factors
Abstract

Blood concentrations of insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) have recently been associated with breast cancer risk, notably in women who developed breast cancer at a young age. Prospective studies published so far, however, were relatively small and odds ratio (OR) estimates imprecise. We present the results of a large prospective case-control study nested within the European Prospective Investigation into Cancer and Nutrition on total IGF-I, IGFBP-3 and breast cancer risk including 1081 incident cases of invasive breast cancer and 2098 matched control subjects. Increasing IGF-I and IGFBP-3 concentrations were associated with a significant increase in breast cancer risk in women who developed breast cancer after 50 years of age (highest vs lowest quintile OR 1.38 (95% confidence interval (CI) 1.02-1.86), P = 0.01, and 1.44 (95% CI 1.04-1.98), P = 0.01, respectively), but no relationship was observed in younger women (OR = 1.03 (95% CI 0.60-1.77), P = 0.81 for IGF-I, and OR = 0.92 (95% CI 0.50-1.70), P = 0.69 for IGFBP-3). There was, however, significant heterogeneity in the relationship of breast cancer with serum IGF-I and IGFBP-3 levels depending on the time interval between blood donation and tumor diagnosis. A reduction in breast cancer risk with increasing IGF-I concentrations was observed in cases with a diagnosis of cancer less than 2 years after blood donation, (OR = 0.76 (95% CI 0.57-1.03)), while an increase in risk was observed for women with a later diagnosis (above or equal to two years after blood collection, OR = 1.51 (95% CI 1.19-1.91)). A similar pattern was observed for IGFBP-3. This study confirms previous findings for an association of serum IGF-I and IGFBP-3 concentrations with breast cancer risk, particularly for women with a later diagnosis of cancer, but it does not support the hypothesis of an involvement of IGF-I in younger women.

DOI10.1677/erc.1.01150
Alternate JournalEndocr. Relat. Cancer
Citation Key10.1677/erc.1.01150
PubMed ID16728585
Grant ListG0401527 / / Medical Research Council / United Kingdom
/ / Wellcome Trust / United Kingdom